Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) | RFA CA 20 020

Opportunity Information: Apply for RFA CA 20 020

The NIH (within the U.S. Department of Health and Human Services) is seeking R33 grant applications for advanced development and validation of emerging biospecimen science technologies that can improve the quality and reliability of biological samples used in cancer research and, where relevant, clinical care. The central problem this opportunity targets is pre-analytical variation: the changes and degradation that can happen to important molecules in a specimen (such as DNA, RNA, proteins, metabolites, or other analytes) during collection, processing, handling, transport, and storage. Because these early steps can strongly influence downstream results, the FOA is focused on technologies that either prevent or reduce specimen damage, or that can measure and verify specimen quality in a defensible, standardized way.

This announcement is specifically for the R33 phase, meaning the work should be beyond early concept and basic feasibility. Applicants are expected to have already addressed the major feasibility uncertainties and to provide supportive preliminary data showing that the technology or method is plausible and working at some level. The funding is intended to push the technology further through refinement, optimization, and rigorous validation so that it becomes credible and adoptable by the broader cancer research community. In practical terms, NIH is looking for innovations that are not just interesting prototypes, but are moving toward well-tested tools, devices, instrumentation platforms, and associated procedures that other labs, biobanks, and clinical research settings could realistically implement.

The kinds of projects that fit this FOA include technologies that preserve or protect biospecimen integrity under real-world conditions, as well as methods that establish verification criteria for quality assessment and quality control. That can include new devices or reagents that stabilize samples at the point of collection, improved workflows that reduce degradation during processing, storage solutions that better maintain analyte stability, or analytical approaches that can quantify specimen quality and detect compromised samples before they are used. A recurring theme is performance across diverse conditions, reflecting the variability in collection environments and handling practices that can introduce bias or noise into cancer studies.

The broader impact NIH is aiming for is improved confidence in downstream analyses and reduced variability across studies, sites, and populations. By minimizing pre-analytical artifacts, these technologies are expected to accelerate and strengthen research in cancer biology, early detection and screening, diagnosis, treatment selection and monitoring, and epidemiology. The FOA also highlights relevance to cancer health disparities, recognizing that inconsistent collection and handling conditions can disproportionately affect certain settings and populations, and that better stabilization and QC methods can support more equitable, comparable research and clinical insights.

Administratively, this is a discretionary grant opportunity (Funding Opportunity Number RFA-CA-20-020; CFDA 93.394). It was created on December 4, 2019, with an original closing date of September 29, 2020. The award ceiling listed is $300,000, and the expected number of awards is 2, indicating a competitive and targeted program. Eligibility is broad and includes many organization types, such as federal-recognized tribal governments and tribal organizations, state and local governments, public and private institutions of higher education, independent school districts, special districts, public housing authorities/Indian housing authorities, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses, with additional eligibility details referenced in the full announcement text.

Finally, the FOA explicitly states that clinical trials are not allowed under this mechanism. The emphasis is on technology development and validation for biospecimen quality and utility, rather than testing an intervention in a clinical trial framework. The expected end result is a set of mature, validated tools and methods that can be adopted to improve biospecimen handling and assessment, leading to more reliable cancer research findings and better translation to clinical applications.

• The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on Dec 04, 2019.
• Applicants must submit their applications by Sep 29, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for RFA CA 20 020

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: